GlassScriptPhysician profile
Vance S Alm
NPI 1578540951
$10,735.21
in general payments reported to CMS, 2019-2025
40 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $317 · 2021: $1,636 · 2022: $1,277 · 2023: $1,707 · 2024: $2,158 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,248 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,248.24 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,328.64 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,540.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $711.83 | 2019-2024 | Wegovy |
| Astellas Pharma US INC | $708.96 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $578.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.25 | 2022-2025 | Caplyta |
| Pfizer INC. | $423.53 | 2019-2025 | |
| Lilly USA, LLC | $358.80 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $332.80 | 2020-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $310.61 | 2019-2021 | |
| Amgen INC. | $282.14 | 2019-2025 | Repatha, Repatha, Otezla |
| Zyla Life Sciences, INC. | $269.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.18 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $240.54 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $200.39 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vance Alm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.